Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 77Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 11Myeloproliferative Disorders 6Hematologic Neoplasms 5Anemia, Refractory, with Excess of Blasts 4Recurrence 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia 3Hematologic Diseases 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2GATA2 Deficiency 2Sarcoma, Myeloid 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pathologic Complete Response 1Neurofibromatosis 1 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1

Interventions

Cytarabine 4venetoclax 2Mitoxantrone 2Daunorubicin 2Cladribine 2quizartinib 1pegylated granulocyte colony-stimulating factor 1Sorafenib 1Razoxane 1Leyk 1Idarubicin 1Gemtuzumab 1Etoposide 1Dexrazoxane 1Bortezomib 1Azacitidine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Azacitidine × 90 days × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡